410.78
Overview
News
Price History
Option Chain
Financials
Why TMO Down?
Discussions
Forecast
Stock Split
Dividend History
Thermo Fisher Scientific Inc stock is traded at $410.78, with a volume of 3.01M.
It is up +0.72% in the last 24 hours and down -2.03% over the past month.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
See More
Previous Close:
$407.85
Open:
$407.07
24h Volume:
3.01M
Relative Volume:
1.35
Market Cap:
$158.51B
Revenue:
$42.90B
Net Income/Loss:
$6.52B
P/E Ratio:
24.09
EPS:
17.05
Net Cash Flow:
$6.72B
1W Performance:
-2.17%
1M Performance:
-2.03%
6M Performance:
-25.55%
1Y Performance:
-28.39%
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Name
Thermo Fisher Scientific Inc
Sector
Industry
Phone
(781) 622-1000
Address
168 THIRD AVENUE, WALTHAM, MA
Compare TMO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TMO
Thermo Fisher Scientific Inc
|
410.78 | 158.51B | 42.90B | 6.52B | 6.72B | 17.05 |
![]()
DHR
Danaher Corp
|
194.82 | 140.78B | 23.82B | 3.77B | 4.90B | 5.15 |
![]()
IDXX
Idexx Laboratories Inc
|
489.98 | 37.91B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
A
Agilent Technologies Inc
|
108.70 | 31.23B | 6.53B | 1.26B | 1.31B | 4.35 |
![]()
IQV
Iqvia Holdings Inc
|
153.29 | 26.31B | 15.41B | 1.37B | 2.11B | 7.50 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-10-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
Dec-23-24 | Initiated | Scotiabank | Sector Perform |
Oct-14-24 | Initiated | Redburn Atlantic | Buy |
Oct-01-24 | Initiated | Stephens | Overweight |
Aug-28-24 | Initiated | Wells Fargo | Overweight |
Jun-03-24 | Resumed | Jefferies | Buy |
Mar-18-24 | Resumed | Citigroup | Neutral |
Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
Jan-08-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
Dec-18-23 | Initiated | HSBC Securities | Buy |
Dec-13-23 | Initiated | Wolfe Research | Outperform |
Oct-26-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
Oct-25-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
Sep-28-23 | Initiated | Bernstein | Outperform |
Sep-06-23 | Resumed | Citigroup | Buy |
Jul-19-23 | Initiated | Raymond James | Outperform |
Jul-19-23 | Reiterated | Robert W. Baird | Outperform |
Jul-13-23 | Upgrade | Credit Suisse | Neutral → Outperform |
Apr-04-23 | Reiterated | Barclays | Overweight |
Dec-14-22 | Initiated | Deutsche Bank | Buy |
Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
Oct-27-22 | Downgrade | The Benchmark Company | Buy → Hold |
Aug-25-22 | Initiated | Credit Suisse | Neutral |
Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
Jan-26-22 | Resumed | Barclays | Overweight |
Oct-20-21 | Upgrade | Citigroup | Neutral → Buy |
Oct-15-21 | Resumed | Cowen | Outperform |
Aug-05-21 | Resumed | Credit Suisse | Outperform |
Jul-16-21 | Initiated | The Benchmark Company | Buy |
Mar-18-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
Mar-03-21 | Initiated | Barclays | Overweight |
Jan-08-21 | Upgrade | Credit Suisse | Neutral → Outperform |
Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
Dec-02-20 | Initiated | Goldman | Buy |
Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
Sep-30-20 | Initiated | Atlantic Equities | Overweight |
Sep-14-20 | Initiated | Morgan Stanley | Overweight |
Aug-20-20 | Resumed | JP Morgan | Overweight |
Jul-15-20 | Upgrade | Cleveland Research | Neutral → Buy |
Jul-07-20 | Reiterated | Needham | Buy |
Apr-23-20 | Reiterated | Needham | Buy |
Jan-31-20 | Reiterated | Needham | Buy |
Jan-22-20 | Initiated | Credit Suisse | Neutral |
Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
Jan-07-20 | Initiated | Citigroup | Buy |
Nov-15-19 | Initiated | Stifel | Buy |
Jul-25-19 | Reiterated | Needham | Buy |
Jul-16-19 | Downgrade | Needham | Strong Buy → Buy |
May-30-19 | Initiated | Wolfe Research | Outperform |
May-23-19 | Reiterated | Needham | Strong Buy |
Apr-22-19 | Reiterated | Needham | Strong Buy |
Apr-16-19 | Reiterated | BofA/Merrill | Buy |
View All
Thermo Fisher Scientific Inc Stock (TMO) Latest News
Digital Genome Market Forecast: Growth Trends, Key Players & - openPR.com
Neuroendocrine Tumor Treatment Market: Investment Analysis & - openPR.com
Tissue Diagnostics Market to Reach $12.4 Billion by 2029, Growing at 7.0% CAGR - GlobeNewswire Inc.
Here's How Much You Would Have Made Owning Thermo Fisher Scientific Stock In The Last 20 Years - Benzinga
Thermo Fisher Scientific Inc. (TMO): Among Billionaire Mario Gabelli’s Large-Cap Stock Picks with Huge Upside Potential - Yahoo Finance
Engineer III, Manufacturing Engineering (Waltham, MA, USA) - The Chemical Engineer Job Board
Thermo Fisher Scientific: 4 Reasons This Oversold Stock Is a Buy - Morningstar
Custom Antibody Market To Hit USD 1,230.09 Billion By 2032 | - openPR.com
High Content Screening Market Global Forecasts 2025-2030 - GlobeNewswire
Smarter protection: New Class II biological safety cabinet - Labmate Online
Thermo Fisher Scientific Inc. (TMO): Among Richard Chilton’s Stock Picks with Huge Upside Potential - Insider Monkey
Thermo Fisher Scientific to Present at BofA Securities 2025 Health Care Conference on May 13 - BioSpace
Thermo Fisher’s new biosafety cabinet offers improved lab safety and user experience - BioSpectrum Asia
Oversold Conditions For Thermo Fisher Scientific (TMO) - Nasdaq
Thermo Fisher Scientific Inc. stock falls Tuesday, underperforms market - MarketWatch
Thermo Fisher CEO Marc Casper to Share Strategic Updates at Major Healthcare Conference - Stock Titan
Benzyl Alcohol Market Scope: Growth, Share, Value, Size, - openPR.com
Global Raman Spectroscopy Market Is Booming So Rapidly - openPR.com
Immune Cell Engineering Market Generated Opportunities, - openPR.com
Laboratory Equipment Market Future Business Opportunities - openPR.com
Genome Engineering Market Generated Opportunities, Future - openPR.com
Is Thermo Fisher Scientific (TMO) One of the Best Falling Stocks to Buy According to Analysts? - Insider Monkey
Thermo Fisher Scientific to cut jobs at Orlando location - Yahoo Finance
RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell & Exosome Therapy Manufacturing - PRWeb
THERMO FISHER SCIENTIFIC INC. SEC 10-Q Report - TradingView
Epigenetics Market Is Booming So Rapidly 2025-2032 -Illumina - openPR.com
Thermo Fisher Scientific Inc (TMO) Stock Analysis: A Closer Look at the 35.79% Potential Upside - DirectorsTalk Interviews
RoosterBio announces collaboration with Thermo Fisher to advance cell therapy manufacturing - BioSpectrum Asia
Thermo Fisher Scientific Leverages Integrated Solutions To Accelerate the Development of Biologic Therapeutics - Technology Networks
RoosterBio and Thermo Fisher Scientific Agree to Collaborate to Advance Cell and Exosome Therapy Manufacturing - Genetic Engineering and Biotechnology News
Lab Automation Market Set to Witness Significant Growth - openPR.com
Thermo Fisher commits $2bn to boost US operations - The Manufacturer
Thermo Fisher Scientific (NYSE:TMO) Collaborates With RoosterBio To Advance Cell Therapy Solutions - simplywall.st
Thermo Fisher reports Q1 growth, charts a steady course for 2025 - BioProcess International
Thermo Fisher Launches Improved Biological Safety Cabinet - Contract Pharma
RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell and Exosome Therapy Manufacturing - PR Newswire
Research Grade Proteins Market to Witness Massive Growth by 2032 - openPR.com
Thermo Fisher Scientific employs an enhanced platform technology - European Pharmaceutical Manufacturer
Cell Lysis Market Growth in Future Scope 2025-2032 | Thermo - openPR.com
Thermo Fisher Scientific Inc. (NYSE:TMO) Q1 2025 Earnings Call Transcript - MSN
RoosterBio, Thermo Fisher Partner to Advance Cell & Exosome Therapy Manufacturing - Contract Pharma
Thermo Fisher (TMO) Target Price Reduced by Argus | TMO Stock Ne - GuruFocus
Thermo Fisher To Buy Phadia For $3.5 Billion - CHEManager Online
Argus Adjusts Price Target on Thermo Fisher Scientific to $470 From $620 - marketscreener.com
Thermo Fisher accelerates development of biologic therapeutics - BioSpectrum Asia
Thermo Fisher Scientific Leverages Integrated Solutions to Accelerate the Development of Biologic Therapeutics - BioSpace
Pharmacogenomics Market Detailed In New Research Report 2025 | - openPR.com
Thermo Fisher Scientific to invest $2 billion to expand US operation - Indian Pharma Post
ENCell and Thermo Fisher Scientific discuss expanded collaboration in cell and gene therapy field - koreabiomed.com
Competent Cells Market Detailed in New Research Report By 2032 | - openPR.com
Thermo Fisher Scientific Announces $2B Investment to Expand U.S. Operations - Thomasnet
Thermo Fisher Scientific Inc Stock (TMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):